Gene · 6607
Papers3,510
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
461 to 480 of 3,510
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Identification of two short peptide motifs from serine/arginine-rich protein ribonucleic acid recognition motif-1 domain acting as splicing regulators. | PeerJ | 2023 | 37744237 | PubTator, text mining | PubMed |
| Base editing: a promising tool to rescue spinal muscular atrophy. | Signal Transduct Target Ther | 2023 | 37743375 | PubTator, text mining | PubMed |
| A Mixed-method Approach to Develop an Ambulatory Module of the SMA Independence Scale. | J Neuromuscul Dis | 2023 | 37742658 | PubTator, text mining | PubMed |
| Muscle: an independent contributor to the neuromuscular spinal muscular atrophy disease phenotype. | JCI Insight | 2023 | 37737261 | PubTator, text mining | PubMed |
| Differential impact on motor unit characteristics across severities of adult spinal muscular atrophy. | Ann Clin Transl Neurol | 2023 | 37735861 | PubTator, text mining | PubMed |
| Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. | Pharmacoecon Open | 2023 | 37731145 | PubTator, text mining | PubMed |
| RNA-based medicine: from molecular mechanisms to therapy. | EMBO J | 2023 | 37728251 | PubTator, text mining | PubMed |
| PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice. | EMBO Mol Med | 2023 | 37724723 | PubTator, text mining | PubMed |
| Pilot Study on Newborn Screening for Spinal Muscular Atrophy. | Endocr Metab Immune Disord Drug Targets | 2023 | 37711122 | PubTator, text mining | PubMed |
| Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen. | Biol Direct | 2023 | 37705059 | PubTator, text mining | PubMed |
| Clinical Phenotype of Pediatric and Adult Patients With Spinal Muscular Atrophy With Four SMN2 Copies: Are They Really All Stable? | Ann Neurol | 2023 | 37695206 | PubTator, text mining | PubMed |
| Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification. | Ann Clin Transl Neurol | 2023 | 37691296 | PubTator, text mining | PubMed |
| Cyclic AMP induces reversible EPAC1 condensates that regulate histone transcription. | Nat Commun | 2023 | 37684224 | PubTator, text mining | PubMed |
| Molecular basis of RNA-binding and autoregulation by the cancer-associated splicing factor RBM39. | Nat Commun | 2023 | 37666821 | PubTator, text mining | PubMed |
Lessons from Real Life Experience: Importance of In-House Sequencing and Smart Ratio-Based Real-Time PCR Outperform Multiplex Ligation-Dependent Probe Amplification in Prenatal Diagnosis for Spinal Muscular Atrophy: Bench to Bedside Diagnosis. | Glob Med Genet | 2023 | 37663644 | PubTator, text mining | PubMed |
| Nucleic acid-based therapeutics for the treatment of central nervous system disorders. | Front Genet | 2023 | 37662844 | PubTator, text mining | PubMed |
| COPI coatomer subunit α-COP interacts with the RNA binding protein Nucleolin via a C-terminal dilysine motif. | Hum Mol Genet | 2023 | 37658769 | PubTator, text mining | PubMed |
| Genomic Sequencing as a First-Tier Screening Test and Outcomes of Newborn Screening. | JAMA Netw Open | 2023 | 37656460 | PubTator, text mining | PubMed |
| Towards understandings of serine/arginine-rich splicing factors. | Acta Pharm Sin B | 2023 | 37655328 | PubTator, text mining | PubMed |
| Precise genome editing of the Kozak sequence enables bidirectional and quantitative modulation of protein translation to anticipated levels without affecting transcription. | Nucleic Acids Res | 2023 | 37650635 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6607/papers?page=24